SPPI Lawsuit Filed: Jakubowitz Law Pursues Claims on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders

New York, New York--(Newsfile Corp. - October 28, 2021) -  Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).



Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7135/101172_245906_logo.jpg

Affected shareholders purchased shares of SPPI between December 27, 2018 and August 5, 2021

Shareholders interested in representing the class of wronged shareholders have until November 1, 2021 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Spectrum Pharmaceuticals, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101172